Sana Biotechnology (NASDAQ:SANA – Free Report) had its price objective lowered by Citigroup to $11.00 in a research report report published on Monday,Benzinga reports. Citigroup currently has a buy rating on the stock.
SANA has been the topic of several other reports. TD Cowen raised Sana Biotechnology to a “strong-buy” rating in a report on Monday, August 24th. Wall Street Zen upgraded Sana Biotechnology from a “sell” rating to a “hold” rating in a research report on Saturday, November 7th. Weiss Ratings cut Sana Biotechnology from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, November 11th. Finally, Bank of America dropped their price target on Sana Biotechnology from $7.00 to $6.00 and set a “buy” rating for the company in a report on Friday, August 14th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Sana Biotechnology currently has an average rating of “Moderate Buy” and an average price target of $9.83.
Get Our Latest Report on Sana Biotechnology
Sana Biotechnology Stock Down 1.6%
Shares of SANA stock opened at $1.85 on Monday. The company has a market capitalization of $554.33 million, a P/E ratio of -3.49 and a beta of 2.30. Sana Biotechnology has a 12-month low of $1.84 and a 12-month high of $5.49. The firm has a 50-day moving average price of $2.62 and a 200 day moving average price of $3.24.
Sana Biotechnology (NASDAQ:SANA – Get Free Report) last issued its quarterly earnings data on Thursday, November 5th. The company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.15) by $0.01. As a group, research analysts expect that Sana Biotechnology will post -0.51 earnings per share for the current year.
Institutional Investors Weigh In On Sana Biotechnology
A number of hedge funds have recently added to or reduced their stakes in SANA. BlackRock Inc. bought a new position in Sana Biotechnology in the 2nd quarter valued at $58,196,000. Canada Pension Plan Investment Board acquired a new stake in shares of Sana Biotechnology in the 2nd quarter valued at $35,662,000. Bank of America Corp DE acquired a new stake in shares of Sana Biotechnology in the 2nd quarter valued at $20,062,000. Alphabet Inc. bought a new stake in shares of Sana Biotechnology during the second quarter worth $9,816,000. Finally, Deutsche Bank AG bought a new stake in shares of Sana Biotechnology during the second quarter worth $2,251,000. Institutional investors own 88.23% of the company’s stock.
Sana Biotechnology Company Profile
Sana Biotechnology, Inc. is a clinical-stage biotechnology company founded in 2018 and headquartered in Seattle. It develops engineered cells intended to treat a range of diseases, including cancer, autoimmune disorders and conditions that may be addressed through cell replacement. The company’s research focuses on modifying cells to improve their therapeutic properties, including approaches designed to help transplanted cells evade immune rejection. Its programs include engineered immune-cell therapies and cell-replacement treatments, such as work involving insulin-producing cells for type 1 diabetes.
Further Reading
- Five stocks we like better than Sana Biotechnology
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Sana Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sana Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
